Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure lowering therapy
Baseline characteristics conveying a multifold higher risk for cardiovascular events and all-cause death mostly represented nonmodifiable risk factors. Treatment with dual therapy as compared to monotherapy was associated with reduction in cardiovascular events. Monotherapy remained most common BP-lowering treatment indicating substantial opportunity for risk reduction by treatment intensification.
Authors
- Jacques Blacher (ORCID: https://orcid.org/0000-0003-4860-4279)
- George S. Stergiou (ORCID: https://orcid.org/0000-0002-6132-0038)
- Claudio Borghi (ORCID: https://orcid.org/0000-0001-8039-8781)
- Anna Castelo‐Branco (ORCID: https://orcid.org/0000-0003-1406-1886)
- Nelly F Ly (ORCID: https://orcid.org/0000-0002-7527-110X)
- Aurore Tricotel
- António Coca (ORCID: https://orcid.org/0000-0001-6968-3266)
- Irfan Khan (ORCID: https://orcid.org/0000-0002-5747-1642)
- Mohamed Abdel-Moneim
- Christopher Seungkyu Lee (ORCID: https://orcid.org/0000-0002-2510-4071)
Institutions
- National and Kapodistrian University of Athens (GR)
- Université Paris Cité (FR)
- Universitat Abat Oliba CEU (ES)
- IQVIA (United Kingdom) (GB)
- University of Sharjah (AE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Sanofi (United States) (US)
- Hôtel-Dieu de Paris (FR)
- IQVIA (France) (FR)
- Sanofi (Mexico) (MX)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of Hypertension
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1097/hjh.0000000000004002
- Citations
- 2
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.78